Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, announced the initiation of the first clinical sites in Europe in collaboration with GEICAM in Spain.
March 12, 2024
· 10 min read